Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the norwegian population

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Maniaol, Angelina H ^a,b   Elsais, Ahmed ^b,j   Lorentzen, Åslaug R ^a,b   Owe, Jone F ^c   Viken, Marte K ^b,j   Sæther, Hanne ^a,b   Flåm, Siri T ^b   Bråthen, Geir ^d   Kampman, Margitta T ^e,k   Midgard, Rune ^f   Christensen, Marte ^g   Rognerud, Anna ^h   Kerty, Emilia ^b,j   Gilhus, Nils Erik ^c,i   Tallaksen, Chantal M E ^a,j   Lie, Benedicte A ^b,j   Harbo, Hanne F ^a,j  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f Molde Hospital   (Norway)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h Lillehammer Hospital   (Norway)

ⁱ UNIVERSITY OF BERGEN   (Norway)

^j UNIVERSITY OF OSLO   (Norway)

^k UNIVERSITY OF TROMSØ   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; TITIN ANTIBODY; UNCLASSIFIED DRUG; HLA DRB1 ANTIGEN; HLA DRB1*15:01 ANTIGEN; HLA-DRB1*15:01 ANTIGEN;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY ONSET MYASTHENIA GRAVIS; FEMALE; GENE; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HLA A GENE; HLA B GENE; HLA C GENE; HLA DRB1 GENE; HUMAN; LATE ONSET MYASTHENIA GRAVIS; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NORWAY; ONSET AGE; RISK ASSESSMENT; ALLELE; CAUCASIAN; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

ADULT; AGE OF ONSET; ALLELES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NORWAY; RISK FACTORS;

EID: 84860727608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036603     Document Type: Article

References (47)

1. Carr AS, Cardwell CR, McCarron PO, McConville J, (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10 46 pp. 1471-2377.
2. Oosterhuis HJ, (1981) Myasthenia gravis. Clin Neurol Neurosurg 83: 105-135.
3. Osserman KE, Genkins G, (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38: 497-537.
4. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD, (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
5. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, et al. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368.
6. Vincent A, Bowen J, Newsom-Davis J, McConville J, (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurology 2: 99-106.
7. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, et al. (2008) IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131: 1940-1952.
8. Meriggioli MN, Sanders DB, (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475-490.
9. Aarli JA, (1999) Late-onset myasthenia gravis: a changing scene. Arch Neurol 56: 25-27.
10. Evoli A, Minisci C, Di SC, Marsili F, Punzi C, et al. (2002) Thymoma in patients with MG: characteristics and long-term outcome. Neurology 59: 1844-1850.
11. Aarli JA, Romi F, Skeie GO, Gilhus NE, (2003) Myasthenia gravis in individuals over 40. Ann N Y Acad Sci 998: 424-431.
12. Aarli JA, (2008) Myasthenia gravis in the elderly: Is it different? Ann N Y Acad Sci 1132: 238-243.
13. Romi F, Skeie GO, Aarli JA, Gilhus NE, (2000) Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 247: 369-375.
14. Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, et al. (2001) Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 58: 885-890.
15. Evoli A, Batocchi AP, Minisci C, Di SC, Tonali P, (2000) Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 48: 1442-1448.
16. Vincent A, (1994) Aetiological factors in development of myasthenia gravis. Adv Neuroimmunol 4: 355-371.
17. Giraud M, Vandiedonck C, Garchon HJ, (2008) Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci 1132: 180-192.
18. International MHC, Autoimmunity Genetics Network, Rioux JD, Goyette P, Vyse TJ, Hammarstrom L, et al. (2009) Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 106: 18680-18685.
19. Feltkamp TE, van den Berg-Loonen PM, Nijenhuis LE, Engelfriet CP, van Rossum AL, et al. (1974) Myasthenia gravis, autoantibodies, and HL-A antigens. Br Med J 1: 131-133.
20. Hammarstrom L, Smith E, Moller E, Franksson C, Matell G, et al. (1975) Myasthenia gravis: studies on HL-A antigens and lymphocyte subpopulations in patients with myasthenia gravis. Clin Exp Immunol 21: 202-215.
21. Fritze D, Herrman C Jr, Naeim F, Smith GS, Walford RL, (1974) HL-A antigens in myasthenia gravis. Lancet 1: 240-242.
22. van den Berg-Loonen EM, Nijenhuis LE, Engelfriet CP, Feltkamp TE, van Rossum AL, et al. (1977) Segregation of HLA haplotypes in 100 families with a myasthenia gravis patient. J Immunogenet 4: 331-340.
23. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR, (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579-601.
24. Newsom-Davis J, Willcox N, Schluep M, Harcourt G, Vincent A, et al. (1987) Immunological heterogeneity and cellular mechanisms in myasthenia gravis. Ann N Y Acad Sci. 505: 12-26.
25. Kida K, Hayashi M, Yamada I, Matsuda H, Yoshinaga J, et al. (1987) Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized types. Ann Neurol 21: 274-278.
26. Pirskanen R, (1976) Genetic associations between myasthenia gravis and the HL-A system. Journal of Neurology, Neurosurgery & Psychiatry 39: 23-33.
27. Vandiedonck C, Raffoux C, Eymard B, Tranchant C, Dulmet E, et al. (2009) Association of HLA-A in autoimmune myasthenia gravis with thymoma. J Neuroimmunol 210: 120-123.
28. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, et al. (1993) Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol 47: 115-122.
29. Hjelmstrom P, Giscombe R, Lefvert AK, Pirskanen R, Kockum I, et al. (1995) Different HLA-DQ are positively and negatively associated in Swedish patients with myasthenia gravis. Autoimmunity 22: 59-65.
30. Janer M, Cowland A, Picard J, Campbell D, Pontarotti P, et al. (1999) A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. Hum Immunol 60: 909-917.
31. Degli-Esposti MA, Andreas A, Christiansen FT, Schalke B, Albert E, et al. (1992) An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 35: 355-364.
32. Vandiedonck C, Beaurain G, Giraud M, Hue-Beauvais C, Eymard B, et al. (2004) Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci U S A 101: 15464-15469.
33. Machens A, Loliger C, Pichlmeier U, Emskotter T, Busch C, et al. (1998) The impact of HLA on long-term outcome after thymectomy for myasthenia gravis. J Neuroimmunol 88: 177-181.
34. Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CI, (1990) Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 31: 285-290.
35. Giraud M, Beaurain G, Yamamoto AM, Eymard B, Tranchant C, et al. (2001) Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 57: 1555-1560.
36. Spurkland A, Gilhus NE, Ronningen KS, Aarli JA, Vartdal F, (1991) Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens 37: 90-93.
37. Machens A, Loliger C, Pichlmeier U, Emskotter T, Busch C, et al. (1999) Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol 91: 296-301.
38. Keesey JC, (2004) Clinical evaluation and management of myasthenia gravis. [Review] [166 refs]. Muscle & Nerve 29: 484-505.
39. Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, et al. (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. [Review] [51 refs]. Neurology 55: 16-23.
40. Lorentzen AR, Karlsen TH, Olsson M, Smestad C, Mero IL, et al. (2009) Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol 65: 658-666.
41. Sayer DC, Whidborne R, De SD, Rozemuller EH, Christiansen FT, et al. (2004) A multicenter international evaluation of single-tube amplification protocols for sequencing-based typing of HLA-DRB1 and HLA-DRB3,4,5. Tissue Antigens 63: 412-423.
42. Dudbridge F, (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25: 115-121.
43. Valdes AM, Thomson G, (1997) Detecting disease-predisposing variants: the haplotype method. Am J Hum Genet 60: 703-716.
44. Svejgaard A, Ryder LP, (1994) HLA and disease associations: detecting the strongest association. Tissue Antigens 43: 18-27.
45. Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, et al. (2004) Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 74: 160-167.
46. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS, (2011) The Etiology of Paraneoplastic Autoimmunity. Clin Rev Allergy Immunol. 10.1007/s12016-010-8248-5 [doi].
47. Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, et al. (2011) Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 2011 847393. 10.4061/2011/847393 [doi].